...
首页> 外文期刊>American journal of bioethics >Equipoise Trumps Randomization
【24h】

Equipoise Trumps Randomization

机译:均衡特朗普随机化

获取原文
获取原文并翻译 | 示例

摘要

Ensuring the adequacy of informed consent is a cornerstone of human subjects’ protection in clinical research. A reasonable axiom regarding what must be disclosed and what ought to be understood relative to informed consent suggests that such information as is relevant to one’s ability to make a decision about participation is required. Wendler (2009) has examined whether understanding randomization is a prerequisite to valid informed consent for participation in a randomized clinical trial. Clearly, data suggest that randomization is not well understood by research subjects (Featherstone and Donovan 1998). However, the failure to grasp the implications of randomization, as explored by Wendler (2009), ultimately reflects the therapeutic misconception (Appelbaum et al. 1987). Subjects in clinical trials must understand that they are participants in a research protocol, and the nature of the research question (i.e., safety or efficacy), and what (if anything) is being compared. They also must understand the risks of the various treatments and the safeguards that are in place to protect them. However, in a randomized clinical trial, it is far less important that subjects understand randomization than that they understand there is a legitimate research issue in play. Arguably, it is less important that subjects understand the specific question than that they are assured, to whatever extent they can appreciate, that a condition of equipoise exists. In this respect, it is far more important that the investigator is convinced that a condition of equipoise exists. Failing that, it may be difficult to justify the investigator’s participation in the research protocol, i.e., their recruitment of research subjects. It is important to consider how clinicians become investigators, and how patients become research subjects, and the nature of the research question, as these issues have far greater impact on the likelihood of the therapeutic misconception than does the subject’s appreciation of randomization.
机译:确保知情同意的充分性是人类受试者在临床研究中得到保护的基石。关于必须披露的信息以及相对于知情同意应理解的合理公理,表明需要这样的信息,即与参与决策的能力有关的信息。 Wendler(2009)研究了理解随机化是否是参与随机临床试验的有效知情同意的前提。显然,数据表明研究对象没有很好地理解随机化(Featherstone和Donovan 1998)。然而,正如Wendler(2009)所探讨的那样,未能把握随机化的含义最终反映了治疗上的误解(Appelbaum et al。1987)。临床试验中的受试者必须了解他们是研究方案的参与者,研究问题的性质(即安全性或有效性)以及正在比较的内容(如果有的话)。他们还必须了解各种治疗的风险以及为保护它们而采取的保障措施。但是,在一项随机临床试验中,让受试者理解随机性与其了解存在合法的研究问题相比显得不那么重要。可以说,让受试者理解具体问题比确保他们在任何程度上都能体会到存在平衡的条件更为重要。在这方面,更重要的是让调查人员确信存在平衡的条件。否则,可能很难证明研究者参与研究方案(即,他们招募研究对象)是合理的。重要的是要考虑临床医生如何成为研究者,患者如何成为研究对象,以及研究问题的性质,因为这些问题对治疗误解的可能性的影响远大于对受试者随机化的认识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号